# South America Neurodegenerative Disease Market

> South America Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions), By Route of Administration (Oral, Injectable, Intravenous, Transdermal) and By Regional (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.71%
- **2024:** $ 3,400 Million
- **2025:** $ 3,662.14 Million
- **2035:** $ 7,700 Million
- **Key Players:** Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co (US), Amgen (US), Sanofi (FR), Pfizer (US)

**Report ID:** MRFR/LS/50857-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-neurodegenerative-disease-market-52616

---

## Market Summary

## **South America Neurodegenerative Disease Market Overview**

As per MRFR analysis, the South America Neurodegenerative Disease Market Size was estimated at 1.1 (USD Billion) in 2023. The South America Neurodegenerative Disease Market Industry is expected to grow from 1.17(USD Billion) in 2024 to 2.12 (USD Billion) by 2035. The South America Neurodegenerative Disease Market CAGR (growth rate) is expected to be around 5.559% during the forecast period (2025 - 2035).

### **Key South America Neurodegenerative Disease Market Trends Highlighted**

The South America neurodegenerative disease market is experiencing several important trends driven by an increasing prevalence of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The aging population in countries like Brazil and Argentina significantly contributes to the rise in these diseases, making it a crucial market driver. Additionally, heightened awareness about neurodegenerative disorders, coupled with improved diagnostic techniques, is encouraging more patients to seek treatment, further boosting the market. Opportunities to be explored in this region include the development of new therapies and advancements in healthcare infrastructure.

Local governments are investing in healthcare systems and research initiatives aimed at enhancing treatment options. Collaborations with international pharmaceuticals can lead to innovative drug development, positioning South America as a key player in the global market. Moreover, the rise of telemedicine has opened avenues for patients to access specialized care, particularly in rural areas where resources are limited. Recent trends also suggest a growth in personalized medicine approaches tailored to individual genetic profiles. 

Clinical trials focusing on neurodegenerative diseases are increasingly conducted in South America, which demonstrates the region's developing capabilities in medical research.Furthermore, public health campaigns tackling stigma associated with neurodegenerative diseases provide greater support for patients and caregivers, thereby fostering a more understanding environment. Overall, these dynamic changes indicate a rapidly evolving landscape in the South American neurodegenerative disease market, emphasizing the need for ongoing adaptation by stakeholders involved in healthcare and research.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America Neurodegenerative Disease Market Drivers**

### **Rising Prevalence of Neurodegenerative Diseases**

The rising frequency of neurodegenerative disorders such as Alzheimer's and Parkinson's disease is driving the South America Neurodegenerative Disease Market. According to health-care predictions, the number of people affected by Alzheimer's disease alone in South America would reach around 7.6 million by 2030, representing a stunning increase from current levels. This growth can be ascribed to reasons such as an aging population, as stated by the Latin American and Caribbean Demographic Centre, which predicts that by 2050, the share of South Americans aged 60 and older would climb by 58%.

Furthermore, important organizations like as the World Health Organization (WHO) stress the importance of effective medicines and care solutions for the rising patient population, driving investment in the South America Neurodegenerative Disease Market Industry. This combination of growing patient numbers and public health directives to enhance neurodegenerative disease care lays the groundwork for market expansion.

### **Advancements in Research and Development**

Significant advancements in Research and Development (R&D) are driving the South America Neurodegenerative Disease Market. With increased funding directed towards innovative treatment methodologies, including gene therapy and personalized medicine, there is a surge in clinical trials targeting neurodegenerative conditions. The Brazilian Ministry of Health recently reported that research funding for neurological disorders increased by 20% over the last four years, fostering new therapeutic options. Additionally, partnerships between academic institutions and pharmaceutical companies are on the rise, enhancing the speed at which new treatments can be developed and brought to market.

These collaborations, such as those initiated by the Federation of Pharmaceutical Industries in Brazil, are vital in driving the South America Neurodegenerative Disease Market Industry forward by introducing effective treatments more rapidly.

### **Increasing Government Support and Initiatives**

The South America Neurodegenerative Disease Market is also benefiting from increasing governmental support and initiatives aimed at addressing these health conditions. Governments across South America are implementing national plans and policies to tackle neurodegenerative diseases, with Brazil leading the charge through its Health Ministry's national Alzheimer's plan. Reports indicate a 30% increase in budget allocation towards neurodegenerative disease programs between 2020 and 2022.These efforts focus not only on awareness campaigns but also on funding for improved healthcare services, making treatments more accessible to patients across the region.

This government focus is crucial in creating a conducive environment for growth in the South America Neurodegenerative Disease Market Industry.

### **Growing Awareness and Education**

There is a significant increase in awareness and education about neurodegenerative diseases in South America, which serves as a market driver. Initiatives led by organizations like the Alzheimer’s Association Latin America chapter are critical in reducing stigma and improving understanding of these diseases among the general public and healthcare professionals.

Educational programs have reported reaching over 1 million people across 10 countries in South America over the past five years, leading to earlier diagnosis and increased demand for treatment options.This heightened awareness is crucial for expanding the South America Neurodegenerative Disease Market Industry, as informed patients are more likely to seek treatment and participate in clinical trials.

## **South America Neurodegenerative Disease Market Segment Insights**

### **Neurodegenerative Disease Market Disease Type Insights**

The South America Neurodegenerative Disease Market is a crucial area of focus within the healthcare landscape, especially when examining it through the lens of Disease Type. This market encompasses various conditions, primarily Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington's Disease, each presenting unique challenges and opportunities for treatment and management. Alzheimer's Disease stands as a leading contributor, indicating a significant burden on both patients and healthcare systems due to its progressive nature and large patient population.

With a growing elderly demographic in South America, the battle against this condition is intensifying, prompting a rise in Research and Development initiatives aimed at developing innovative therapies. Parkinson's Disease also plays a prominent role, as it affects a considerable segment of the population and presents symptoms that can severely impact the quality of life, highlighting the urgent need for effective therapies. Multiple Sclerosis is gaining attention as well, with an increasing awareness of its prevalence within South America and the associated healthcare costs. This condition adds to the growing focus on managing chronic neurodegenerative disorders. 

Meanwhile, Amyotrophic Lateral Sclerosis, though less common, presents critical challenges due to its aggressive nature and limited treatment options, requiring focused research efforts to improve patient outcomes. Huntington's Disease, further, while not as prevalent, contributes to the discussions around genetic factors in neurodegeneration, thereby influencing future avenues for both public health policy and targeted treatment developments. Overall, the South America Neurodegenerative Disease Market segmentation illustrates a landscape that is expected to evolve significantly as healthcare systems adapt to manage the increasing prevalence of these disorders.

The emphasis on tailored treatment approaches and advancements in medical technology will be essential, creating not only challenges but also opportunities within the South American region as healthcare initiatives strive to address these debilitating conditions. With a concerted effort among stakeholders, including governments and healthcare providers, there lies great potential for improving the quality of care and outcomes for patients suffering from these neurodegenerative diseases in South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Neurodegenerative Disease Market Diagnosis Method Insights**

The Diagnosis Method segment of the South America Neurodegenerative Disease Market plays a crucial role in the effective identification and management of various neurodegenerative disorders. This segment encompasses several essential techniques, including Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, and Electrophysiological Tests. Neurological Examination serves as the first step for clinicians, allowing for a thorough assessment of patient symptoms, thus facilitating early detection.

Imaging Techniques, such as MRI and CT scans, are significant for visualizing structural changes in the brain associated with neurodegenerative diseases, contributing to accurate diagnosis.Cerebrospinal Fluid Analysis provides valuable insights into biochemical changes in the central nervous system, helping differentiate between various conditions. Electrophysiological Tests are integral in evaluating the electrical activity of the nervous system, providing diagnostic clarity, especially in conditions like Alzheimer's and Parkinson's disease. The increasing adoption of advanced diagnostic technologies and the growing prevalence of neurodegenerative diseases in South America are key drivers for this market segment's expansion.

As awareness about these diseases continues to rise, the relevance of diverse diagnostic methods is expected to gain even more prominence in the region's healthcare landscape.

### **Neurodegenerative Disease Market Treatment Type Insights**

The Treatment Type segment of the South America Neurodegenerative Disease Market exhibits a diverse range of therapeutic approaches, including Medication, Therapy, Rehabilitation, and Surgical Interventions. Medication remains a cornerstone for managing symptoms and slowing disease progression, making it a crucial aspect of treatment strategies in the region.

Therapy, encompassing physical and cognitive interventions, plays an essential role in maintaining patients' quality of life and independence, particularly given the growing elderly population in South America.Rehabilitation services are significantly important, as they aid patients in recovering or improving their functional abilities, which is increasingly relevant due to the rising prevalence of neurodegenerative disorders across the region. Surgical Interventions, while less common, are critical for certain conditions, offering definitive solutions that can substantially alleviate symptoms.

The integration of innovative research and advancements in treatment methodologies continues to drive the market, presenting opportunities for stakeholders to enhance care delivery and outcomes for patients afflicted with neurodegenerative diseases in South America.While challenges exist, including access to therapies and varying healthcare infrastructure across countries, the overall trajectory of the Treatment Type segment indicates ongoing evolution and a potential for improved patient outcomes through focused efforts.

### **Neurodegenerative Disease Market Route of Administration Insights**

The Route of Administration segment within the South America Neurodegenerative Disease Market plays a crucial role in the delivery and effectiveness of treatments for conditions such as Alzheimer's and Parkinson's diseases. Various methods, including Oral, Injectable, Intravenous, and Transdermal routes, cater to diverse patient needs and preferences. Oral administration is often favored for its convenience and ease of use, thus facilitating patient compliance, while Injectable forms may provide rapid and more controlled delivery of medications, particularly for acute situations.

The Intravenous route is significant for its ability to administer therapies quickly into the bloodstream, which is vital for urgent care settings. Transdermal delivery offers a non-invasive alternative that can enhance patient comfort and adherence, especially for those who may struggle with swallowing or self-injections. The increasing prevalence of neurodegenerative diseases in South America drives demand for innovative and effective delivery methods, making this segment a focal point for market growth.

Additionally, advancements in technology are leading to the development of novel formulations that improve the efficacy and patient experience across all administration routes, reflecting broader trends within the South America Neurodegenerative Disease Market industry.

## **South America Neurodegenerative Disease Market Key Players and Competitive Insights**

The South America Neurodegenerative Disease Market is experiencing significant growth, driven by an increasing prevalence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. The competitive landscape in this region is characterized by a variety of pharmaceutical companies that are actively developing and marketing therapies aimed at treating these complex conditions. Key players are focusing on innovative drug development, strategic collaborations, and expanding their product portfolios to meet the rising demand for effective treatments. This competitive arena is further intensified by the necessity for ongoing research and development, which seeks to yield breakthroughs that can offer improved patient outcomes.

The varying regulatory environments and healthcare infrastructure across South American countries also play a crucial role in shaping the competitive dynamics within this market.Merck is prominently positioned in the South America Neurodegenerative Disease Market, demonstrating a strong commitment to addressing the needs of patients suffering from neurodegenerative disorders. The company’s strengths lie in its robust portfolio of innovative therapies and its active involvement in clinical trials aimed at further enhancing its offerings.

With a well-established presence in key South American countries, Merck benefits from extensive distribution networks and strategic partnerships that facilitate the delivery of its products to healthcare providers and patients alike. The company's investments in local research initiatives and collaborations with medical institutions strengthen its competitive edge by ensuring that it remains at the forefront of developments in neurodegenerative disease treatments tailored to the regional population's needs. 

Merck's focus on patient-centric solutions and commitment to improving healthcare accessibility solidify its strong standing in the market.Sanofi also plays a significant role in the South America Neurodegenerative Disease Market, with a portfolio that includes essential therapies for Alzheimer’s and other related conditions. The company is dedicated to research and development, which is reflected in its innovative product offerings tailored specifically for the South American population. Sanofi’s market presence is enhanced by its strategic mergers and acquisitions that have expanded its research capabilities and product line while strengthening its distribution channels across the region.

The company's commitment to collaborative partnerships with local health authorities and research institutions further establishes its footprint in neurodegenerative diseases. Sanofi leverages its extensive experience in the pharmaceutical industry to continue developing effective treatment solutions, thereby maintaining its competitive advantages in addressing the unique challenges faced by patients and healthcare providers in South America.

**Key Companies in the South America Neurodegenerative Disease Market Include**

- Merck
- [Sanofi](https://www.sanofi.com/en/your-health/medicines/neurology)
- Takeda
- AbbVie
- Pfizer
- Bristol Myers Squibb
- GlaxoSmithKline
- Johnson & Johnson
- AstraZeneca
- Novartis
- Roche
- Biogen
- Eli Lilly
- Amgen
- Mylan

## **South America Neurodegenerative Disease Market Industry Developments**

Recent developments in the South America Neurodegenerative Disease Market indicate a growing focus on enhancing therapeutic options and addressing significant health challenges. In August 2023, AstraZeneca launched a new clinical trial to evaluate the efficacy of its Alzheimer’s treatment in Brazil, marking an important milestone in providing innovative solutions locally. Additionally, Merck has announced investments in local R&D initiatives aimed at tailoring treatments to the specific genetic profiles prevalent in the South American population.

In the realm of mergers and acquisitions, in September 2023, AbbVie announced the acquisition of a local biotech firm specializing in neurotherapy, enhancing its capability to deliver targeted treatments throughout the region. Furthermore, the market has seen valuation growth with companies like Pfizer significantly increasing their presence, reflecting an increasing demand for therapies addressing neurodegenerative diseases. Over the last two to three years, initiatives by Biogen in terms of collaboration with local health agencies have also been noteworthy, focusing on Alzheimer’s awareness and treatment accessibility, impacting overall market dynamics positively.

The South American government is highly engaged in addressing these diseases, promoting public health initiatives to tackle the growing prevalence of neurodegenerative conditions throughout the region.

## **South America Neurodegenerative Disease Market Segmentation Insights**

### **Neurodegenerative Disease Market Disease Type****Outlook**

- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Huntington's Disease

### **Neurodegenerative Disease Market Diagnosis Method****Outlook**

- Neurological Examination
- Imaging Techniques
- Cerebrospinal Fluid Analysis
- Electrophysiological Tests

### **Neurodegenerative Disease Market Treatment Type****Outlook**

- Medication
- Therapy
- Rehabilitation
- Surgical Interventions

### **Neurodegenerative Disease Market Route of Administration****Outlook**

- Oral
- Injectable
- Intravenous
- Transdermal

### **Neurodegenerative Disease Market Regional****Outlook**

- Brazil
- Mexico
- Argentina
- Rest of South America

## Market Drivers

### Aging Population in South America

The aging population in South America is a critical driver for the neurodegenerative disease market. As life expectancy increases, the incidence of neurodegenerative disorders such as Alzheimer's and Parkinson's disease is expected to rise. By 2030, it is projected that the population aged 65 and older will account for approximately 15% of the total population in South America. This demographic shift creates a growing demand for effective treatments and care solutions within the neurodegenerative disease market. Furthermore, the increasing burden on healthcare systems necessitates innovative approaches to manage these conditions, thereby driving investment in research and development. The economic implications are substantial, with potential costs related to care and treatment reaching billions of dollars annually, highlighting the urgency for advancements in this sector.

### Increased Awareness and Education

Increased awareness and education regarding neurodegenerative diseases significantly impact the neurodegenerative disease market in South America. Public health campaigns and educational initiatives have led to a better understanding of these conditions among both healthcare professionals and the general population. This heightened awareness encourages early diagnosis and intervention, which is crucial for effective management of neurodegenerative disorders. As a result, there is a growing demand for diagnostic tools and therapeutic options, contributing to market expansion. Moreover, the emphasis on patient education empowers individuals to seek medical advice sooner, potentially improving outcomes. The market is likely to see a surge in innovative products and services tailored to meet the needs of an informed patient population, further driving growth in this sector.

### Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a pivotal driver for the neurodegenerative disease market in South America. Governments and private entities are increasingly recognizing the need to enhance healthcare facilities and services to address the rising prevalence of neurodegenerative disorders. This investment includes the establishment of specialized clinics, research centers, and rehabilitation facilities aimed at improving patient care. For instance, funding for research initiatives has seen a notable increase, with allocations reaching millions of dollars annually. Enhanced infrastructure not only facilitates better access to care but also fosters collaboration between researchers and clinicians, leading to advancements in treatment options. As healthcare systems evolve, the neurodegenerative disease market is poised for growth, driven by improved service delivery and innovative therapeutic solutions.

### Technological Advancements in Treatment

Technological advancements in treatment modalities are transforming the neurodegenerative disease market in South America. Innovations such as [telemedicine](https://www.marketresearchfuture.com/reports/telemedicine-market-2216), artificial intelligence, and personalized medicine are reshaping how these disorders are diagnosed and managed. For example, telehealth services have expanded access to specialists, allowing patients in remote areas to receive timely consultations. Additionally, the integration of AI in drug discovery processes is accelerating the development of new therapies, potentially leading to breakthroughs in treatment. The market is witnessing a shift towards more targeted and effective interventions, which could improve patient outcomes significantly. As these technologies continue to evolve, they are likely to attract investment and drive competition within the neurodegenerative disease market, fostering a dynamic environment for growth.

### Rising Economic Burden of Neurodegenerative Diseases

The rising economic burden of neurodegenerative diseases is a significant driver for the neurodegenerative disease market in South America. As the prevalence of these disorders increases, the associated healthcare costs are expected to escalate dramatically. Estimates suggest that the economic impact of neurodegenerative diseases could reach billions of dollars annually, encompassing direct medical expenses and indirect costs such as lost productivity. This financial strain on families and healthcare systems underscores the urgent need for effective treatments and preventive measures. Policymakers are likely to prioritize funding for research and development in this area, aiming to alleviate the economic burden while improving patient care. Consequently, the neurodegenerative disease market may experience accelerated growth as stakeholders seek solutions to address this pressing issue.

## Future Outlook

The [Neurodegenerative Disease Market](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) is projected to grow at a 7.71% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in therapeutics, and rising healthcare investments.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring
- Investment in AI-driven drug discovery technologies
- Expansion of personalized medicine approaches for treatment optimization

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased healthcare focus.

## Segment Insights

### By Disease Type: Alzheimer's Disease (Largest) vs. Parkinson's Disease (Fastest-Growing)

In the South America neurodegenerative disease market, the distribution of market share among disease types reveals that Alzheimer's Disease holds the largest share, driven by high diagnosis rates and the aging population. Parkinson's Disease, while holding a smaller share, is emerging rapidly due to increasing awareness and advancements in treatment options. Growth trends for these segments indicate a significant rise in cases for both Alzheimer's and Parkinson's Diseases. The increasing prevalence of risk factors, including lifestyle changes and environmental impacts, plays a crucial role in the rising incidence of these conditions. Furthermore, the development of new therapies and supportive care options is paving the way for faster growth in the Parkinson's Disease segment, appealing to both patients and healthcare providers.

Alzheimer's Disease (Dominant) vs. Amyotrophic Lateral Sclerosis (Emerging)

Alzheimer's Disease is recognized as the dominant segment due to its high incidence rates and significant attention from healthcare systems and research initiatives. Its market position reflects extensive investments in diagnostic and therapeutic innovations aimed at improving patient care. Conversely, Amyotrophic Lateral Sclerosis (ALS) is considered an emerging segment, gaining increased focus due to rising awareness and advocacy efforts. Despite a smaller patient base, ALS is positioned for growth, benefitting from advancements in research and emerging treatments that enhance quality of life for those affected. Both segments signify substantial shifts in treatment paradigms and healthcare priorities in the region.

### By Treatment Type: Medication (Largest) vs. Physical Therapy (Fastest-Growing)

In the South America neurodegenerative disease market, the treatment type segment is mainly dominated by Medication, accounting for a considerable proportion of the market share. The significance of Medication lies in its established role in managing symptoms and improving quality of life for patients with neurodegenerative diseases. Following Medication, Physical Therapy has emerged as a key player, capturing a growing share of the market as more individuals seek rehabilitation services tailored to their specific needs.

Medication (Dominant) vs. Physical Therapy (Emerging)

Medication remains the dominant treatment type within the South America neurodegenerative disease market, largely due to the extensive range of pharmaceutical options available for conditions such as Alzheimer’s and Parkinson’s disease. Medications are critical for symptom management, enabling patients to maintain some level of independence. In contrast, Physical Therapy is recognized as an emerging treatment option, driven by an increasing focus on holistic care and rehabilitation. This segment is expanding rapidly, as healthcare practitioners emphasize the importance of physical rehabilitation in enhancing mobility and function in patients, thereby improving overall quality of life.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the South America neurodegenerative disease market, age group segmentation reveals that older adults, particularly individuals aged 65 and above, account for the largest percentage of patients diagnosed with neurodegenerative conditions. This age bracket constitutes the primary focus for pharmaceutical and healthcare solutions aimed at addressing diseases such as Alzheimer's and Parkinson's. Meanwhile, gender distribution shows that males exhibit a slightly higher prevalence of certain neurodegenerative diseases, highlighting a critical demographic in need of targeted treatment strategies.
The growth trends in this demographic segment are influenced by the aging population in South America, leading to an increase in neurodegenerative disease diagnoses. Additionally, gender-specific factors such as hormonal changes and lifestyle choices are contributing to the growing recognition of the need for tailored healthcare solutions. As awareness of neurodegenerative diseases rises, there is an increasing push for research and treatment options tailored specifically for these demographic groups.

Age Group: 65+ (Dominant) vs. Gender: Male (Emerging)

The age group of 65 and above is the dominant segment in the South America neurodegenerative disease market, as it encompasses the majority of diagnosed cases. This segment is characterized by a high prevalence of conditions such as Alzheimer's disease and other dementias, necessitating focused healthcare strategies to manage symptoms and improve quality of life. On the other hand, the male population is an emerging segment, as recent studies suggest a faster-growing incidence of neurodegenerative diseases among men due to various risk factors. The contrasting dynamics of these two segments emphasize the necessity for healthcare providers to develop specialized programs that cater not only to the dominant aging population but also to the rising concerns related to male patients.

### By Stage of Disease: Early Stage (Largest) vs. Advanced Stage (Fastest-Growing)

In the South America neurodegenerative disease market, the analysis of the 'Stage of Disease' segment indicates that the Early Stage holds the largest market share due to the increasing incidence of early diagnosis and preventive care initiatives. This stage benefits from a growing awareness of neurodegenerative conditions, leading to earlier interventions and treatment strategies. Conversely, the Advanced Stage is witnessing rapid growth driven by an aging population and the escalating prevalence of progressive neurodegenerative disorders, marking it as the fastest-growing segment in this market landscape.

Growth trends for the 'Stage of Disease' segment are influenced by various factors including advancements in medical technology, increased governmental support for research, and evolving healthcare policies that prioritize early intervention and management of neurodegenerative diseases. The rise in diagnostic prevalence, particularly for conditions like Alzheimer's and Parkinson's disease, is propelling the growth of both the Early and Advanced stages, reflecting a market that is transitioning towards earlier diagnosis while addressing the needs of patients at more progressive stages of disease.

Early Stage (Dominant) vs. Advanced Stage (Emerging)

The Early Stage of neurodegenerative diseases is currently the dominant segment in South America, characterized by proactive healthcare measures focused on prevention and early detection. This stage encompasses patients who have been diagnosed with mild symptoms, allowing for intervention strategies that can slow disease progression. The market sees extensive investment in educational programs to promote awareness of early signs and symptoms. On the other hand, the Advanced Stage is emerging as a significant focus area due to the demographic trends of an aging population. Patients in this stage experience more pronounced symptoms requiring intensive care and management strategies. The increasing burden of advanced cases drives research and development aimed at improving quality of life and treatment options, positioning this segment as a key area for future market growth.

### By Healthcare Setting: Hospitals (Largest) vs. Home Care (Fastest-Growing)

In the South America neurodegenerative disease market, the distribution of healthcare settings reveals that hospitals hold the largest share, leveraging their extensive resources and specialist staff to cater to complex cases. Outpatient clinics and rehabilitation centers follow, offering targeted therapies while contributing significantly to the overall market. Home care services, however, are emerging as a pivotal player, reflecting a shift towards more personalized care for patients managing chronic conditions, fostering growth in this segment.

Hospitals (Dominant) vs. Home Care (Emerging)

Hospitals in the South America neurodegenerative disease market are positioned as the dominant healthcare setting, equipped with advanced facilities and specialized personnel to provide comprehensive treatment plans for complex cases. Their extensive reach allows them to serve a diverse patient population, ensuring top-tier diagnostic and therapeutic services. In contrast, home care services are rapidly gaining traction as an emerging segment, driven by the increasing demand for patient-centered care. This shift towards home care is motivated by factors such as convenience, cost-effectiveness, and a patient's preference for receiving treatment in familiar environments, solidifying its important role in managing neurodegenerative diseases.

## Regional Market Share Analysis

### Brazil : Strong Demand and Growth Drivers

Brazil holds a dominant position in the South American neurodegenerative disease market, accounting for approximately 45% of the total market share with a value of $1450.0 million. Key growth drivers include an aging population, increasing prevalence of neurodegenerative disorders, and enhanced healthcare access. Government initiatives, such as the National Health System's focus on chronic diseases, and improved healthcare infrastructure are also pivotal in driving demand and consumption patterns.

### Mexico : Increasing Awareness and Investment

Mexico represents a significant portion of the South American neurodegenerative disease market, valued at $800.0 million, which is about 25% of the regional share. The market is driven by rising awareness of neurodegenerative conditions and increased investment in healthcare infrastructure. Regulatory policies are evolving to support innovative treatments, while local consumption patterns show a growing preference for advanced therapies and personalized medicine.

### Argentina : Focus on Innovative Treatments

Argentina's neurodegenerative disease market is valued at $600.0 million, contributing around 20% to the South American total. The growth is fueled by a combination of increasing healthcare expenditure and a focus on innovative treatment options. Government initiatives aimed at enhancing research and development in the healthcare sector are also significant. Demand trends indicate a shift towards more specialized care and therapies tailored to specific conditions.

### Rest of South America : Varied Demand Across Countries

The Rest of South America, with a market value of $550.0 million, represents about 10% of the regional share. This sub-region faces unique challenges, including varying healthcare policies and economic conditions across countries. However, there is a growing demand for neurodegenerative treatments, driven by an increase in awareness and healthcare access. Local governments are beginning to prioritize neurodegenerative diseases in their health agendas, fostering a more supportive environment for market growth.

## Competitive Benchmarking

The neurodegenerative disease market in South America is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as Biogen (US), Eli Lilly (US), and Roche (CH) are strategically positioned to leverage their extensive research capabilities and established market presence. Biogen (US) focuses on advancing its pipeline of therapies for Alzheimer's disease, while Eli Lilly (US) emphasizes partnerships to enhance its drug development processes. Roche (CH) is investing heavily in personalized medicine, which appears to be a significant trend shaping the competitive environment. Collectively, these strategies indicate a shift towards more targeted and effective treatment options, thereby intensifying competition among these major players.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure is moderately fragmented, with several players vying for market share. However, the influence of key players remains substantial, as they continue to set benchmarks for innovation and quality in the neurodegenerative disease sector. This competitive structure suggests that while there is room for new entrants, established companies maintain a stronghold through their advanced capabilities and resources.
In October 2025, Biogen (US) announced a collaboration with a local biotech firm to develop a novel treatment for Alzheimer's disease, which could potentially enhance its market position in South America. This strategic move not only underscores Biogen's commitment to innovation but also reflects a growing trend of partnerships aimed at accelerating drug development. Such collaborations may lead to more rapid advancements in treatment options, thereby benefiting patients and strengthening Biogen's competitive edge.
In September 2025, Eli Lilly (US) launched a new initiative focused on [digital health](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636)solutions for neurodegenerative diseases, aiming to integrate technology into patient care. This initiative is significant as it aligns with the broader trend of digitalization in healthcare, potentially improving patient outcomes and engagement. By embracing technology, Eli Lilly is likely to enhance its service offerings, thereby differentiating itself in a crowded market.
In August 2025, Roche (CH) unveiled a new personalized medicine approach for treating Parkinson's disease, which is indicative of the company's strategic focus on tailored therapies. This development is crucial as it highlights Roche's commitment to addressing the unique needs of patients, which may lead to improved treatment efficacy. Such innovations are likely to set Roche apart from competitors, reinforcing its leadership position in the market.
As of November 2025, current trends in the neurodegenerative disease market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards innovation, technology, and supply chain reliability. This transition may redefine how companies approach market entry and product development, ultimately benefiting patients through enhanced therapeutic options.

## Recent News & Developments

Recent developments in the South America Neurodegenerative Disease Market indicate a growing focus on enhancing therapeutic options and addressing significant health challenges. In August 2023, AstraZeneca launched a new clinical trial to evaluate the efficacy of its Alzheimer’s treatment in Brazil, marking an important milestone in providing innovative solutions locally. Additionally, Merck has announced investments in local R&D initiatives aimed at tailoring treatments to the specific genetic profiles prevalent in the South American population.

In the realm of mergers and acquisitions, in September 2023, AbbVie announced the acquisition of a local biotech firm specializing in neurotherapy, enhancing its capability to deliver targeted treatments throughout the region. Furthermore, the market has seen valuation growth with companies like Pfizer significantly increasing their presence, reflecting an increasing demand for therapies addressing neurodegenerative diseases. Over the last two to three years, initiatives by Biogen in terms of collaboration with local health agencies have also been noteworthy, focusing on Alzheimer’s awareness and treatment accessibility, impacting overall market dynamics positively.

The South American government is highly engaged in addressing these diseases, promoting public health initiatives to tackle the growing prevalence of neurodegenerative conditions throughout the region.

## Report Scope

| MARKET SIZE 2024 | 3400.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 3662.14(USD Million) |
| MARKET SIZE 2035 | 7700.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.71% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co (US), Amgen (US), Sanofi (FR), Pfizer (US) |
| Segments Covered | Disease Type, Diagnosis Method, Treatment Type, Route of Administration |
| Key Market Opportunities | Advancements in personalized medicine and digital health technologies enhance treatment options in the neurodegenerative disease market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory adaptations in the neurodegenerative disease market. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What is the current valuation of the South America neurodegenerative disease market?**
A: The market valuation was 10.24 USD Billion in 2024.

**Q: What is the projected market size for the South America neurodegenerative disease market by 2035?**
A: The market is expected to reach 22.93 USD Billion by 2035.

**Q: What is the expected CAGR for the South America neurodegenerative disease market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.6% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the South America neurodegenerative disease market?**
A: Key players include Roche, Novartis, Bristol-Myers Squibb, Eli Lilly and Company, Biogen, Sanofi, Merck & Co., Amgen, and AstraZeneca.

**Q: What are the major disease types contributing to the South America neurodegenerative disease market?**
A: Major disease types include Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis.

**Q: How does the market segment by treatment type look in terms of valuation?**
A: The treatment type segment includes Medication at 3.5 to 8.0 USD Billion, Physical Therapy at 1.5 to 3.5 USD Billion, and Supportive Care at 3.44 to 7.33 USD Billion.

**Q: What demographic factors are influencing the South America neurodegenerative disease market?**
A: Demographic factors include Age Group, Gender, Socioeconomic Status, Geographic Distribution, and Ethnicity, with valuations ranging from 1.7 to 5.5 USD Billion.

**Q: How is the market segmented by the stage of disease?**
A: The stage of disease segment includes Early Stage at 2.06 to 4.67 USD Billion and Advanced Stage at 2.55 to 5.83 USD Billion.

**Q: What healthcare settings are involved in the South America neurodegenerative disease market?**
A: Healthcare settings include Hospitals at 3.06 to 7.0 USD Billion and Home Care at 2.06 to 4.5 USD Billion.

**Q: What trends are anticipated in the South America neurodegenerative disease market by 2035?**
A: The market is likely to experience growth driven by advancements in treatment options and increasing patient demographics.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-neurodegenerative-disease-market-52616*